Allspring Global Investments Holdings LLC Sells 88 Shares of DaVita Inc. (NYSE:DVA)

Allspring Global Investments Holdings LLC lessened its position in shares of DaVita Inc. (NYSE:DVA) by 4.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,041 shares of the company’s stock after selling 88 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in DaVita were worth $306,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. FMR LLC grew its stake in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after acquiring an additional 108,446 shares during the last quarter. JPMorgan Chase & Co. grew its position in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares in the last quarter. KBC Group NV increased its stake in DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after acquiring an additional 67,250 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in DaVita during the third quarter valued at approximately $10,346,000. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DVA. Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $162.80.

DaVita Stock Performance

DVA opened at $143.08 on Wednesday. DaVita Inc. has a twelve month low of $124.42 and a twelve month high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $11.45 billion, a PE ratio of 13.32, a PEG ratio of 1.07 and a beta of 0.93. The firm’s 50-day moving average price is $160.77 and its 200 day moving average price is $158.21.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.